Decitabine also inhibited DNMT1 activity, and its effect on multiple cancers has also been studied in patients with AML (ClinicalTrials.gov Identifier: NCT00416598), refractory diffuse-large B-cell lymphoma (ClinicalTrials.gov Identifier: NCT03579082), follicular thyroid cancer (ClinicalTrials.gov Identifier: NCT00085293), etc. However, although several clinical trials have been carried out for these two drugs, their impact on drug resistance is rarely involved. The gene discussed is DNMT1; the disease is acute myeloid leukemia.